Tm Bioscience Adds Two New Cytochrome P450 (CYP) Mutation Detection Kits to its Pharmacogenomics Product Menu
16:19 EDT Tuesday, June 01, 2004
- Tag-It(TM) P450-2C9 and Tag-It(TM) P450-2C19 Mutation Detection Kits
Enable Efficient Testing -
TORONTO, June 1 /CNW/ - Tm Bioscience Corporation (Toronto, Ontario; TSX: TMC), an emerging leader in the commercial genetic testing market, today announced the launch of two new Tag-It(TM) Mutation Detection Kits for the P450-2C9 and P450-2C19 genes. These kits identify the presence or absence of important mutations in liver enzymes that are common in patients with atypical drug metabolism, which can lead to adverse drug reactions (ADRs), a leading cause of death in the US. According to the U.S. Food and Drug Administration (FDA), ADRS are responsible for $136 billion in annual healthcare costs, which is greater than the total cost for either cardiovascular or diabetic care.
"As a leading provider of clinical mutation detection kits, Tm Bioscience is focused on offering its customers a comprehensive suite of toxicology tests that are at the forefront of the new revolution in healthcare," stated Greg Hines, CEO. "Cytochrome P450 testing is key to detecting mutations in genes known to affect drug metabolism. These latest products, in concert with our already marketed Tag-It P450-2D6 mutation detection kit, provide clinical laboratories with the ability to efficiently and accurately test for 26 critical mutations affecting drug metabolism, which, we believe, will ultimately improve patient care."
Scientists estimate that 90% of currently available prescription drugs are metabolized by P450-derived enzymes. The Tag-It(TM) suite of P450 kits is a cost-effective, high-quality solution that provides laboratories with a predictive tool to evaluate possible adverse drug reactions. The Tag-It(TM) Mutation Detection Kit for P450-2C9 provides simultaneous detection of 5 different mutations of Cytochrome P450 in a multiplex format, and the Tag-It(TM) Detection Kit for P450-2C19 provides simultaneous detection of 7 mutations in a multiplex format. Multiplexing enables laboratories to simultaneously test patients for numerous mutations, providing broad information to physicians involved in pharmacogenomics.
Pharmacogenomic testing is rapidly becoming a part of responsible medical practice. It gives physicians the ability to know in advance how a patient will metabolize prescribed medications, reducing the risk of ADRs and making it possible to prescribe the right dose for maximum therapeutic effect the first time.
About Tag-It(TM) genetic tests
Tm Bioscience's product menu is focused in the fields of human genetic disorders, pharmacogenetics and infectious disease. The Company has already commercialized a series of Tag-It(TM) tests for coagulation genes, launched in December 2002; the Tag-It(TM) P450-2D6 test, first in a series of tests for drug metabolism genes; and the Tag-It(TM) CFTR 40+4 test, launched in September 2003. The Company's pre-commercial pipeline includes an Ashkenazi Jewish panel combining several common hereditary disease gene tests. All genetic tests from Tm Bioscience are based on the Tag-It(TM) Universal Array platform, which utilizes a proprietary universal tag system that allows for easy optimization, product development and expansion. Assays from Tm operate on the Luminex xMAP(R) system, a bead based instrument growing in popularity. Combined, the Universal Array and Luminex instrument enable the rapid production of flexible, highly accurate, high-throughput, low-cost DNA-based tests.
About Tm Bioscience - Putting the Human Genome to Work(TM)
Tm Bioscience is a DNA-based diagnostics company developing a suite of
genetic tests. Tm Bioscience's product pipeline includes tests for genetic mutations related to hematology, cystic fibrosis, drug metabolism and other debilitating genetic disorders. Tm Bioscience is located in Toronto, Ontario. Additional information about Tm Bioscience can be found at www.tmbioscience.com.
/For further information: INVESTOR RELATIONS CONTACTS: Equicom Group Contact (Canada): James Smith, The Equicom Group, Tel.: (416) 815-0700, Fax: (416) 815-0080, Email: jsmith(at)equicomgroup.com; Euro RSCG Life NRP Contact (U.S.): Sharon Weinstein, Account Supervisor, Euro RSCG Life NRP, Tel.: (212) 845-4271, Fax: (212) 845-4260, Email: sharon.weinstein(at)eurorscg.com; To request a free copy of this organization's annual report, please go to http://www.newswire.ca
and click on reports(at)cnw./